See the DrugPatentWatch profile for mirabegron
Mirabegron is a medication used to treat overactive bladder (OAB) symptoms, including urinary urgency, frequency, and incontinence. As of December 2023, there is no FDA-approved generic version of mirabegron available in the United States [1].
When will generic mirabegron be available?
The availability of a generic version of mirabegron depends on patent expirations and potential legal challenges. According to DrugPatentWatch.com, the relevant patents for mirabegron are set to expire in the coming years, which typically opens the door for generic manufacturers to seek approval [2]. However, specific generic launch dates are contingent on regulatory approval processes and any ongoing patent litigation.
What is the brand name for mirabegron?
Mirabegron is marketed under the brand name Myrbetriq in the United States [1].
How does mirabegron work?
Mirabegron works by relaxing the detrusor muscle, a muscle in the bladder wall. This relaxation allows the bladder to store more urine, thereby reducing the symptoms of urgency and frequency associated with OAB [1]. It acts as a beta-3 adrenergic agonist.
What are the side effects of mirabegron?
Common side effects of mirabegron can include increased blood pressure, urinary tract infection, headache, and constipation [1]. Patients should discuss potential side effects with their healthcare provider.
Can other medications treat overactive bladder?
Yes, other medications are available to treat overactive bladder. These often include anticholinergic drugs, which work by relaxing bladder muscles through a different mechanism. Examples include oxybutynin, tolterodine, and solifenacin [3]. Behavioral therapies and lifestyle changes can also be effective treatments for OAB.
What is the cost of mirabegron?
The cost of brand-name mirabegron can be significant. Once a generic version becomes available, the price is typically expected to decrease substantially [2]. Patient assistance programs may be available for those who have difficulty affording the medication.
---
Sources
1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?fuseaction=genNew.DailyList
2. https://drugpatentwatch.com/
3. https://www.nhs.uk/conditions/overactive-bladder/